ADVENTRX Completes Acquisition of SynthRx
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
CeQur Develops Diabetes Compliance Device
An important drawback of current diabetes treatment regimens is patient compliance, particularly for insulin injections that are painful and must also be timely administered.
Accord Biosciences To Present At OneMedForum NY 2011
Nitric oxide is one of the most important physiological signaling molecules in the body, responsible for regulating such fundamental biological processes as proper blood vessel function and the body’s defense against infection.
Ikonisys Develops Prenatal Diagnosis of Rare Genetic Disorders
Ikonisys is a medical devices company that has developed a combinatorial technological platform using molecular biology and imaging methodology for the detection of rare cells, […]
Del Mar Pharmaceuticals Is Fighting Cancer One Molecule At A Time
Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.
MEDomics to Present At OneMedForum NY 2011
OneMedForum NY 2011 welcomes MEDomics, LLC, a molecular diagnostic laboratory, confirmed to present in June at the annual conference.
Aduro Biotech, OneMedForum SF Presenting Company, Announces $20 Million Financing
Aduro BioTech, a OneMedForum presenting company is engineering Listeria to treat Pancreatic Cancer and other infectious diseases.
New Software From iCAD Helps Doctors Diagnose Prostate Cancer
New software being used at Englewood Hospital and Medical Center should help detect prostate cancer earlier, eliminate unnecessary testing procedures and help form a treatment plan.
VisEn Medical Develops New Light Based Diagnostics
Technology that enables the fast and sensitive detection of biological and disease specific markers in live tissue is a major need in the diagnostic field. […]
OneMedForum NY 2011 Grows Its Advisory Board And Selects Initial Presenters
OneMedForum NY 2011, to be held June 23 -24, has added new members to the Advisory Board and selected an initial group of “discovery” lesser known companies with terrific growth potential.